Clinical Trial

Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 19, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response rate (MPR).
Trial Details
NCT Number NCT06374901
Lead Sponsor Xiangdong Cheng
Collaborators: Liaoning Cancer Hospital & Institute, Shanxi Province Cancer Hospital, Sichuan Cancer Hospital and Research Institute, The Second Affiliated Hospital of Harbin Medical University
Conditions Gastric Cancer
Enrollment 134 participants
Start Date 2024-04-25
Primary Completion 2026-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-19